Mouse xenograft models for drug discovery in pancreatic cancer

Belen Rubio-Viqueira, Manuel Hidalgo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It is estimated that the development of a new anticancer agent costs US $800-1,000 million and takes over a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns whether such models are predictive of drug efficacy in humans, supporting the development of alternative approaches. Furthermore, a general transition has been observed from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to target-orientated drug screening of agents with defined mechanisms of action. New approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamic and pharmacokinetic properties of the tested drug. This chapter focuses on the classical and new preclinical screening models and techniques for anticancer drug development.

Original languageEnglish (US)
Title of host publicationDrug Discovery in Pancreatic Cancer: Models and Techniques
PublisherSpringer New York
Pages29-49
Number of pages21
ISBN (Print)9781441911599
DOIs
StatePublished - 2010

Fingerprint

Drug Discovery
Pancreatic Neoplasms
Heterografts
Preclinical Drug Evaluations
Pharmaceutical Preparations
Antineoplastic Agents
Molecular Models
Cytotoxins
Human Development
Pharmacokinetics
Costs and Cost Analysis
Neoplasms

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Rubio-Viqueira, B., & Hidalgo, M. (2010). Mouse xenograft models for drug discovery in pancreatic cancer. In Drug Discovery in Pancreatic Cancer: Models and Techniques (pp. 29-49). Springer New York. https://doi.org/10.1007/978-1-4419-1160-5_2

Mouse xenograft models for drug discovery in pancreatic cancer. / Rubio-Viqueira, Belen; Hidalgo, Manuel.

Drug Discovery in Pancreatic Cancer: Models and Techniques. Springer New York, 2010. p. 29-49.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rubio-Viqueira, B & Hidalgo, M 2010, Mouse xenograft models for drug discovery in pancreatic cancer. in Drug Discovery in Pancreatic Cancer: Models and Techniques. Springer New York, pp. 29-49. https://doi.org/10.1007/978-1-4419-1160-5_2
Rubio-Viqueira B, Hidalgo M. Mouse xenograft models for drug discovery in pancreatic cancer. In Drug Discovery in Pancreatic Cancer: Models and Techniques. Springer New York. 2010. p. 29-49 https://doi.org/10.1007/978-1-4419-1160-5_2
Rubio-Viqueira, Belen ; Hidalgo, Manuel. / Mouse xenograft models for drug discovery in pancreatic cancer. Drug Discovery in Pancreatic Cancer: Models and Techniques. Springer New York, 2010. pp. 29-49
@inbook{c69715f619ee46d8b1672302c5e1ecc9,
title = "Mouse xenograft models for drug discovery in pancreatic cancer",
abstract = "It is estimated that the development of a new anticancer agent costs US $800-1,000 million and takes over a decade between conception and approval. However, 90{\%} of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns whether such models are predictive of drug efficacy in humans, supporting the development of alternative approaches. Furthermore, a general transition has been observed from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to target-orientated drug screening of agents with defined mechanisms of action. New approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamic and pharmacokinetic properties of the tested drug. This chapter focuses on the classical and new preclinical screening models and techniques for anticancer drug development.",
author = "Belen Rubio-Viqueira and Manuel Hidalgo",
year = "2010",
doi = "10.1007/978-1-4419-1160-5_2",
language = "English (US)",
isbn = "9781441911599",
pages = "29--49",
booktitle = "Drug Discovery in Pancreatic Cancer: Models and Techniques",
publisher = "Springer New York",

}

TY - CHAP

T1 - Mouse xenograft models for drug discovery in pancreatic cancer

AU - Rubio-Viqueira, Belen

AU - Hidalgo, Manuel

PY - 2010

Y1 - 2010

N2 - It is estimated that the development of a new anticancer agent costs US $800-1,000 million and takes over a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns whether such models are predictive of drug efficacy in humans, supporting the development of alternative approaches. Furthermore, a general transition has been observed from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to target-orientated drug screening of agents with defined mechanisms of action. New approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamic and pharmacokinetic properties of the tested drug. This chapter focuses on the classical and new preclinical screening models and techniques for anticancer drug development.

AB - It is estimated that the development of a new anticancer agent costs US $800-1,000 million and takes over a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns whether such models are predictive of drug efficacy in humans, supporting the development of alternative approaches. Furthermore, a general transition has been observed from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to target-orientated drug screening of agents with defined mechanisms of action. New approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamic and pharmacokinetic properties of the tested drug. This chapter focuses on the classical and new preclinical screening models and techniques for anticancer drug development.

UR - http://www.scopus.com/inward/record.url?scp=84900182358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900182358&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1160-5_2

DO - 10.1007/978-1-4419-1160-5_2

M3 - Chapter

AN - SCOPUS:84900182358

SN - 9781441911599

SP - 29

EP - 49

BT - Drug Discovery in Pancreatic Cancer: Models and Techniques

PB - Springer New York

ER -